Table 4.
AUEtotal of GLP-1, glucose, and insulin after a single oral dose (day 1) or at the steady state after multiple doses (day 10) of evogliptin 5 mg, 10 mg, or 20 mg
| Treatment group | Average AUEtotal (CV%)
|
|||||
|---|---|---|---|---|---|---|
| Day 1
|
Day 10
|
|||||
| GLP-1 (pM·h) |
Glucose (h·mg/dL) |
Insulin (h·μIU/mL) |
GLP-1 (pM·h) |
Glucose (h·mg/dL) |
Insulin (h·μIU/mL) |
|
| Baseline corrected | ||||||
| Placebo (N=6) | 14.8 (28.5) | 335.4 (25.1) | 401.8 (42.9) | 14.6 (39.7) | 323.9 (27.9) | 462.6 (42.9) |
| Evogliptin 5 mg (N=8) | 25.7 (48.3) | 264.1 (36.1) | 238.3 (15.0) | 25.4 (56.7) | 259.4 (25.2) | 270.9 (36.0) |
| Evogliptin 10 mg (N=8) | 24.9 (46.0) | 234.9 (24.9) | 315.1 (35.7) | 22.2 (41.0) | 242.8 (41.6) | 410.2 (62.6) |
| Evogliptin 20 mg (N=8) | 45.3 (73.8) | 229.7 (37.6) | 223.3 (50.8) | 35.5 (67.3) | 209.3 (31.0) | 301.3 (28.6) |
| Baseline uncorrected | ||||||
| Placebo (N=6) | 46.8 (68.0) | 851.4 (5.2) | 440.5 (38.5) | 48.1 (57.2) | 836.6 (7.0) | 506.5 (38.7) |
| Evogliptin 5 mg (N=8) | 55.8 (49.6) | 741.3 (14.1) | 274.9 (14.2) | 75.7 (111.2) | 759.6 (9.1) | 311.3 (32.0) |
| Evogliptin 10 mg (N=8) | 55.0 (35.9) | 747.3 (6.0) | 360.2 (30.6) | 52.6 (25.0) | 751.4 (12.6) | 460.3 (57.2) |
| Evogliptin 20 mg (N=8) | 82.8 (55.3) | 747.8 (11.9) | 264.7 (44.0) | 72.8 (37.0) | 727.0 (7.2) | 349.5 (24.7) |
Notes: AUEtotal was for the following time periods: 4–6 hours, 10–12 hours, and 24–26 hours on day 1, and 220–222 hours, 226–228 hours, and 240–242 hours on day 10.
Abbreviations: AUEtotal, total area under the effect–time curve; CV%, percentage of coefficient of variation; GLP-1, glucagon-like peptide-1.